Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA 1 ) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD).
Tamera J CorteLisa LancasterJeffrey J SwigrisToby M MaherJonathan G GoldinScott M PalmerTakafumi SudaTakashi OguraAnne MinnichXiaojiang ZhanGiridhar S TirucheraiBrandon ElpersHong XiaoHideaki WatanabeR Adam SmithEdgar D CharlesAryeh FischerPublished in: BMJ open respiratory research (2022)
NCT04308681.